qualitop-antibody

The Project

The aim of QUALITOP is to serve as a dedicated digital platform for assembling data on the health and quality of life among cancer patients receiving immunotherapy throughout Europe. Through an analysis of multiple data sources, such as genetics, lifestyle, and psychosocial factors, the goal is to predict any adverse effects and to determine what factors influence patients’ well-being. It will improve care coordination and cost-effectiveness by delivering real-time recommendations based on patient data through machine learning.

Signup to our Newsletter

The Consortium

The QUALITOP Consortium is highly complementary and unique, including 14 organisations from Belgium, France, Germany, Italy, Netherlands, Portugal, Spain, United Kingdom and United States.

Partners

Latest News

Cancer Patients Europe joins Qualitop

A significant stride towards enhancing the quality of life for cancer patients, Cancer Patients Europe (CPE) has joined the consortium to lend support to the mission of Qualitop and amplify […]

Publication on: “Monitoring multidimensional aspects of quality of life after cancer immunotherapy: protocol for the international multicentre, observational QUALITOP cohort study”

Abstract Introduction:  Immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy, have significantly improved the clinical outcomes of various malignancies. However, they also cause immune-related adverse events […]

Publication on: “Quality of life after treatment with immune checkpoint inhibitors for lung cancer; the impact of age”

Abstract Introduction:  Immune checkpoint inhibitors (ICIs) have revolutionized lung cancer treatment. However, it remains unclear as to whether changes in Health-Related Quality-of-Life (HRQoL) are associated with the age of lung […]

Contact Us

Start typing and press Enter to search